Iżrael - Ebrajk - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg / 1 ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

padagis israel agencies ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg/ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

samsung bioepis il ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

pfizer pharmaceuticals israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

dexcel ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Iżrael - Ebrajk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pen - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

Iżrael - Ebrajk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pfs - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r